Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-003264-65-GB
EUCTR2006-003264-65-GB
Active, not recruiting
Phase 1

A Proof-of-Concept Study to evaluate the benefit from add-on therapy with montelukast versus salmeterol in children with asthma carrying the Arg/Arg-16 beta2-receptor genotype

niversity of Dundee0 sitesJanuary 8, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAsthmaMedDRA version: 8.1Level: LLTClassification code 10003553Term: Asthma
DrugsSeretideFlixotideSingulair

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Asthma
Sponsor
niversity of Dundee
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 8, 2009
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity of Dundee

Eligibility Criteria

Inclusion Criteria

  • •All children and adolescents (5\-18 years) with asthma in Tayside (Scotland) known (a) to carry the Arg/Arg\-16 genotype and (b) currently on inhaled steroids and (c) inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had (a) any school absences from asthma or (b) out\-of\-hours visits to GP/hospital visits/admissions or NHS 24 contacts due to asthma over the previous 12 months. All patients fulfilling the above inclusion criteria will be invited to participate in the study.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •The presence of serious respiratory or multi\-system disease (e.g. cystic fibrosis, cancer under current treatment) will constitute exclusion criteria for the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Add-on salmeterol versus montelukast in Arg/Arg-16 asthmatics
ISRCTN49849003niversity of Dundee (UK)120
Completed
Not Applicable
A proof of concept study to evaluate the impact of a food supplement on uptake and anti-inflammatory properties of omega-3 fatty acid derived specialized pro-resolution lipid mediatorsHealthy volunteers
DRKS00023304Evonik Operations GmbH19
Completed
Not Applicable
A proof of concept study to evaluate the impact of a food supplement on production of short chain fatty acids and microbiome in healthy subjectshealthy volunteers
DRKS00023166Evonik Operations GmbH18
Completed
Phase 1
An Intralesional Injection Study of DUR-928 in Psoriasis PatientsPsoriasisSkin - Dermatological conditions
ACTRN12616001077459INC Research12
Active, not recruiting
Phase 1
A Proof of concept study to investigate the effect of the antiviral medication Telbivudine in patients with inflammatory heart muscle disease caused by the ParvovirusParvovirus B19-induced inflammatory cardiomyopathyTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-004825-17-DECharité Universitätsmedizin Berlin25